Medscape4d
Ensitrelvir Shows Promise for COVID-19 Prevention Following Exposure
The lack of available medications in the United States for COVID post-exposure prophylaxis leaves household members in close ...
pharmaphorum2d
Enanta lawsuit claims Pfizer's Paxlovid infringes its patent
However, it "seeks fair compensation for Pfizer's use of a coronavirus 3CL protease inhibitor claimed in the '953 patent." There's a potential third wheel in the dispute, according to SVB ...
pharmaphorum1d
Six months after authorization, what do we know about Paxlovid?
How does the drug work? The active drug is nirmatrelvir, a protease inhibitor, which helps keep the SARS-CoV-2 protein from replicating. SARS-CoV-2-3CL protease is an enzyme COVID-19 needs to ...
Business Wire6d
Late-Breaking at CROI 2025: SCORPIO-PEP Phase 3 Trial: Ensitrelvir is the First and Only COVID-19 Oral Antiviral to Demonstrate Prevention of COVID-19 as Post Exposure Prophylaxis
Stopping COVID-19 pRogression with early Protease InhibitOr treatment – Post-Exposure Prophylaxis (SCORPIO-PEP) assessing ensitrelvir (Generic name: ensitrelvir fumaric acid, Code No.: S-217622 ...